Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesDividends payablesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Bruker (BRKRP) Non-Current Deffered Revenue (2010 - 2025)

Bruker posted quarterly Non-Current Deffered Revenue of $109.1 million for Q4 2025, up 9.1% year-on-year from $100.0 million in Q4 2024, and up 9.1% on a QoQ basis from $100.0 million in Q4 2024.

Bruker (BRKRP) has 16 years of Non-Current Deffered Revenue data on file, last reported at $109.1 million in Q4 2025.

  • For the quarter ending Q4 2025, Non-Current Deffered Revenue rose 9.1% year-over-year to $109.1 million; the trailing twelve-month figure through Dec 2025 stood at $109.1 million (up 9.1% YoY), and the FY2025 full-year result was $109.1 million, up 9.1% from the prior year.
  • Non-Current Deffered Revenue for Q4 2025 stood at $109.1 million, up from $100.0 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $109.1 million in Q4 2025 and bottomed at $50.2 million in Q4 2021.
  • The 5-year median for Non-Current Deffered Revenue is $97.1 million (2024), against an average of $93.3 million.
  • The widest annual swing landed in 2022, when Non-Current Deffered Revenue jumped 102.39%; it then decreased 9.94% in 2023.
  • A 5-year view of Non-Current Deffered Revenue shows it stood at $50.2 million in 2021, then surged by 102.39% to $101.6 million in 2022, then retreated by 9.94% to $91.5 million in 2023, then advanced by 9.29% to $100.0 million in 2024, then grew by 9.1% to $109.1 million in 2025.
  • The last three Non-Current Deffered Revenue figures came in at $109.1 million (Q4 2025), $100.0 million (Q4 2024), and $94.2 million (Q3 2024), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Deffered Revenue (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn -
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn -
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn -
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn -
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn -
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn 512.79 Mn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn -
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn -
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn -
10 Bruker - - 379.80 Mn -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 109.10 Mn
Dec 31, 2024 100.00 Mn
Sep 30, 2024 94.20 Mn
Jun 30, 2024 93.90 Mn
Mar 31, 2024 105.60 Mn
Dec 31, 2023 91.50 Mn
Dec 31, 2022 101.60 Mn
Dec 31, 2021 50.20 Mn
Dec 31, 2020 50.90 Mn
Dec 31, 2019 42.80 Mn
Dec 31, 2018 38.30 Mn
Dec 31, 2017 48.70 Mn
Dec 31, 2016 46.80 Mn
Dec 31, 2015 44.40 Mn
Dec 31, 2014 37.10 Mn
Dec 31, 2013 33.70 Mn
Dec 31, 2012 34.90 Mn
Dec 31, 2011 32.70 Mn
Dec 31, 2010 29.30 Mn